Plasbumin-5 Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Plasbumin-5 market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to several factors, including an increase in surgical procedures, trauma, and burn management, an aging population, a rise in liver diseases, and the increasing prevalence of sepsis.

Growth during the market's forecast period is expected to be driven by the rising prevalence of hypoalbuminemia, a greater number of plasma fractionation facilities, a higher demand for albumin in research and development, the expansion of non-therapeutic applications, and increased investments in life sciences. Key trends for the forecast period include a higher utilization of albumin in critical care, an increasing demand for personalized medicine, broader indications, progress in combination therapies, and a rise in applications for cirrhosis and hepatorenal syndrome.

The growing number of surgical procedures is expected to drive the expansion of the plasbumin-5 market. Advancements in medical technology, improved access to healthcare, and an increasing demand for cosmetic and corrective surgeries are key factors contributing to this rise. Plasbumin-5 serves as a volume expander, helping maintain blood volume, blood pressure, and tissue perfusion during surgeries. It also assists in managing hypoproteinemia and supports post-surgery recovery and healing. For instance, in March 2023, the British Association of Aesthetic Plastic Surgeons reported that 31,057 cosmetic surgeries were performed in the UK in 2022, representing a 102% increase from the previous year. This growing number of surgical procedures is fueling the growth of the plasbumin-5 market.

The increasing incidence of burn injuries is also expected to drive the growth of the plasbumin-5 market. Burn injuries, which can damage the skin and underlying tissues, are caused by heat, chemicals, electricity, radiation, or friction. Factors such as heat exposure, household accidents, and workplace hazards contribute to the rise in burn injuries. Plasbumin-5 helps restore blood volume, maintain circulatory pressure, and improve protein levels, which are crucial for supporting fluid balance and tissue repair in burn victims. It also helps prevent edema, reduces the risk of shock, and promotes faster recovery by maintaining osmotic pressure. According to a report from the American Burn Association in August 2024, there were 32,540 burn cases in 2023, an increase from 30,135 in 2022, bringing the total to 156,073 cases over five years. As such, the rising number of burn injuries is driving the growth of the plasbumin-5 market.

The growing prevalence of liver disease is expected to further boost the growth of the Plasbumin-5 market. Liver disease encompasses conditions that impair liver function, including infections, fatty liver, cirrhosis, and liver cancer. Contributing factors include excessive alcohol consumption, obesity, poor diet, and genetic predispositions. Plasbumin-5 helps restore protein levels in patients with liver disease, supporting fluid balance and reducing edema and ascites. It also helps maintain oncotic pressure, which is vital for proper circulation and organ function in these patients. For example, in July 2023, the Office for Health Improvement and Disparities reported 82,290 hospital admissions in England due to liver disease in the 2022 financial year, representing a rate of 150.6 per 100,000 people, an increase from the previous year’s 67,458 admissions. This rise in liver disease prevalence is driving the growth of the plasbumin-5 market.

The key company operating in the plasbumin-5 market is Grifols Therapeutics LLC.

North America was the largest region in the plasbumin-5 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in plasbumin-5 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Plasbumin-5 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plasbumin-5 is a sterile albumin solution sourced from human plasma, formulated to act as a volume expander for patients who have experienced significant fluid loss. This highly purified solution helps restore blood volume, stabilize blood pressure, and enhance the transport of essential substances within the body.

The main formulations of plasbumin-5 are liquid and lyophilized (powder). The liquid version is a ready-to-use intravenous solution designed for quick administration in emergency or clinical settings to rapidly replenish albumin levels. It comes in various packaging sizes, such as 50 milliliters (mL), 250 milliliters (mL), and 500 milliliters (mL), and is used to treat a variety of clinical conditions, including hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass surgery, and acute liver failure. It is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies and is administered to both adult and geriatric patients.

The plasbumin-5 market research report is one of a series of new reports that provides plasbumin-5 market statistics, including the plasbumin-5 industry global market size, regional shares, competitors with the plasbumin-5 market share, detailed plasbumin-5 market segments, market trends, and opportunities, and any further data you may need to thrive in the plasbumin-5 industry. This plasbumin-5 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The plasbumin-5 market consists of sales of human albumin intravenous solutions, sterile, and ready-to-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.